ConductScience.org, home

Comparison · NCT00088413-deaths

Colorectal Cancer vs Non-Colorectal Cancer Cohort vs Breast and Ovarian Cohorts: deaths from any cause

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Colorectal Cancer vs Non-Colorectal Cancer Cohort vs Breast and Ovarian Cohorts: deaths from any cause. Trial comparisons, record NCT00088413-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00088413-deaths

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.040.00710.195wilson
Risk in group 2000.129wilson
Risk difference, group 1 minus group 20.04-0.09290.195newcombe hybrid score
Risk ratio, group 1 over group 2loga group has no participants with the outcome
Odds ratio, group 1 over group 2loga cell of the two-by-two table is zero
Number needed to harm, for one more death from any cause on Colorectal Cancer vs Non-Colorectal Cancer Cohort than on Breast and Ovarian Cohorts25from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Colorectal Cancer vs Non-Colorectal Cancer Cohort
Patients with histologically confirmed measurable or evaluable metastatic colorectal cancer or patients with surgically resected metastatic disease at high risk for recurrence who had completed at least one 5-fluorouracil/(5-FU) containing chemotherapy regimen (e.g., 5-fluorouracil/leucovorin (5-FU/LV) with or without either irinotecan or oxaliplatin or patients that have had an elevated serum CEA (\>5 ugg/L) at any point during their disease course who have failed or not a candidate for standard therapy.
125EG000
Group 2Breast and Ovarian CohortsPatients with evaluable, metastatic breast or ovarian cancer who have failed or not a candidate for standard therapy.026EG001

Harm

What it counts
Total, all-cause mortality
Time frame
Date treatment consent signed to date off study, approximately 164 months and 10 days.

Source ClinicalTrials.gov

Trial

Title
PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer
NCT number
NCT00088413
Phases
PHASE1, PHASE2
Conditions
Adenocarcinoma, Colorectal Cancer, Ovarian Cancer, Breast Cancer
Interventions
PANVAC-V, PANVAC-F, Sargramostim (GM-CSF, Leukine)
Lead sponsor
National Cancer Institute (NCI)
Results first posted
2019-04-16

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT00088413-deaths